The company's total funding stands to $40.2 million to date. The post S Korean exosome biotech firm ILIAS Biologics raises $20.6m in Series B round appeared first on DealStreetAsia.
Chinese biotech company BioCytogen has recently completed a series D+ round of financing of RMB970 million yuan. This round of financing was led by CMB International, followed by SDIC Ventures, China Life Equity, Bencao Capital, Tongchuangweiye and Pax Capital. This financing will be mainly used to support the rapid implementation of the company's cooperation with [...] Chinese Biotech Firm BioCytogen Raises RMB970 Million comes from China Money Network: Primary Data for China's Primary Markets! All Rights Reserved.
Seattle Biotech Startup Led By Adaptive, Fred Hutch Vets Raises $16M For Rapid Drug Development Tech
Lumen Bioscience today announced a $16 million Series B round to help support its novel approach to rapid and low-cost drug development. The company has come up with a way to produce orally-delivered antibodies and other biologics by using a bioengineered bright green algae called Spirulina. It has three clinical programs to treat gastrointestinal diseases including C. difficile, norovirus, and traveler's diarrhea. Lumen CEO Brian Finrow said the company's technology lowers the cost of biologic drugs by a factor of 1,000 or more.
Chinook Therapeutics, a biotech company creating targeted therapies for kidney diseases, raised an additional $106 million just before its planned merger with Aduro Biotech. Chinook said it will have at least $275 million in operating capital following the investment and merger. New investors include EcoR1 Capital, OrbiMed, funds managed by Rock Springs Capital, Avidity Partners, Surveyor Capital (a Citadel company), Ally Bridge Group, Monashee Investment Management LLC, Northleaf Capital Partners, Janus Henderson Investors, Sphera Biotech.
The drug industry is shattering capital-raising records in 2020, as investors funnel money into pharmaceutical and biotech companies. Business Insider spoke with top venture capitalists about why this is happening and how they plan to take advantage. Several VCs said they are advising biotechs that are now considering going public earlier than expected because of the booming public market. Biotech is still a risky gambit, VCs say, but money has flowed into the space as other industries, clobbered by the pandemic, appear shakier than usual. For more stories like this, sign up here for our healthcare newsletter, Dispensed.
New Cyrus Biotechnology Antibody Structure Prediction Software "nextgen" Outperforms Schrodinger And Other Software In Third-party Test | Business Wire
SEATTLE--(BUSINESS WIRE)--New Cyrus software can help develop more effective and safe antibody biologic therapeutics. : SEATTLE--(BUSINESS WIRE)--Cyrus Biotechnology, Inc., today announced it has developed new antibody structure prediction software, Cyrus NextGen, that is significantly more accurate than other leading methods according to a third-party test administered by BIOCAD. NextGen will allow the development of more effective and safe antibody biologic therapeutics by Cyrus and its partners across a range of disease indications.
Chinese innovative biotech firm Lepu Biotech completed a nearly RMB1.291 billion(US$186 million) series B round of financing co-led by Riverhead Capital, Sunshine Insurance Group and Ping An Capital. SDIC Unity Capital, Haitong Innovation Capital Management and State New Central Enterprises Operating Investment Fund also participated in this round. Founded in 2018, Lepu Biotech is a [...] Riverhead Capital Co-Leads $186M Series B Round In Chinese Lepu Biotech comes from China Money Network: Primary Data for China's Primary Markets! All Rights Reserved.
Chinese innovative biotech firm Lepu Biotech completed a nearly RMB1.291 billion(US$186 million) series B round of financing co-led by Riverhead Capital, Sunshine Insurance Group and Ping An Capital. SDIC Unity Capital, Haitong Innovation Capital Management and State New Central Enterprises Operating Investment Fund also participated in this round. Founded in 2018, Lepu Biotech is a Chinese biotech firm focusing on development of cancer diagnosis and therapy. The company, through its nine subsidiaries, has established a comprehensive industrial platform for target discovery, drug development, and drug production.
Gero plans to use the funds to continue developing its AI platform for analysing clinical and genetic data. The post Singapore biotech startup Gero raises $2.2m in Series A round appeared first on DealStreetAsia.
Covid-19 could drive biotech stocks for years to come, experts say, as investors try to pinpoint the next big winner to churn out a vaccine or treatment. The post Why The Coronavirus Pandemic Could Influence Biotech Stocks For Years To Come appeared first on Investor's Business Daily.